112 related articles for article (PubMed ID: 18544445)
21. Integrating targeted agents into therapeutic regimens for patients with resectable colorectal cancer.
Marshall JL
Clin Colorectal Cancer; 2008 Dec; 7 Suppl 2():S63-6. PubMed ID: 19064409
[TBL] [Abstract][Full Text] [Related]
22. Epirubicin, cisplatin and protracted venous infusion 5-Fluorouracil chemotherapy for advanced salivary adenoid cystic carcinoma.
Ross PJ; Teoh EM; A'hern RP; Rhys-Evans PH; Harrington KJ; Nutting CM; Gore ME
Clin Oncol (R Coll Radiol); 2009 May; 21(4):311-4. PubMed ID: 19201585
[TBL] [Abstract][Full Text] [Related]
23. Treatment of multiple myeloma in the targeted therapy era.
Saad AA; Sharma M; Higa GM
Ann Pharmacother; 2009 Feb; 43(2):329-38. PubMed ID: 19193585
[TBL] [Abstract][Full Text] [Related]
24. Combination targeted therapy in advanced renal cell carcinoma.
Sosman J; Puzanov I
Cancer; 2009 May; 115(10 Suppl):2368-75. PubMed ID: 19402058
[TBL] [Abstract][Full Text] [Related]
25. Salivary Gland Cancers: Biology and Systemic Therapy.
Goyal G; Mehdi SA; Ganti AK
Oncology (Williston Park); 2015 Oct; 29(10):773-80. PubMed ID: 26470903
[TBL] [Abstract][Full Text] [Related]
26. Epidermal growth factor receptor immunoexpression evaluation in malignant salivary gland tumours.
Monteiro LS; Bento MJ; Palmeira C; Lopes C
J Oral Pathol Med; 2009 Jul; 38(6):508-13. PubMed ID: 19317849
[TBL] [Abstract][Full Text] [Related]
27. Systemic therapy for advanced or metastatic colorectal cancer: National Comprehensive Cancer Network guidelines for combining anti-vascular endothelial growth factor and anti-epidermal growth factor receptor monoclonal antibodies with chemotherapy.
Engstrom PF;
Pharmacotherapy; 2008 Nov; 28(11 Pt 2):18S-22S. PubMed ID: 18980548
[TBL] [Abstract][Full Text] [Related]
28. Optimizing the treatment of patients with rituximab-pretreated recurrent indolent non-Hodgkin lymphoma.
Leonard JP; Gregory SA; Maloney DG; Vose JM; Younes A; Zelenetz AD
Clin Adv Hematol Oncol; 2008 Jun; 6(6):437-45. PubMed ID: 18567989
[TBL] [Abstract][Full Text] [Related]
29. Herceptin plus chemotherapy in relapsed and/or metastatic salivary gland cancer.
Locati LD; Rinaldi G; Bossi P; Dagrada GP; Quattrone P; Cantú G; Licitra L
Oral Oncol; 2005 Jan; 41(1):97-8. PubMed ID: 15598592
[No Abstract] [Full Text] [Related]
30. Advanced bladder cancer: status of first-line chemotherapy and the search for active agents in the second-line setting.
Gallagher DJ; Milowsky MI; Bajorin DF
Cancer; 2008 Sep; 113(6):1284-93. PubMed ID: 18629841
[TBL] [Abstract][Full Text] [Related]
31. New targeted therapies for non-small-cell lung cancer: a focus on the epidermal growth factor receptor.
Crawford J
J Natl Compr Canc Netw; 2003 Jan; 1 Suppl 1():S78-86. PubMed ID: 19795580
[TBL] [Abstract][Full Text] [Related]
32. Systemic therapy in the management of metastatic or advanced salivary gland cancers.
Lagha A; Chraiet N; Ayadi M; Krimi S; Allani B; Rifi H; Raies H; Mezlini A
Head Neck Oncol; 2012 May; 4():19. PubMed ID: 22558945
[TBL] [Abstract][Full Text] [Related]
33. Palliative chemotherapy in patients with salivary gland neoplasms and preliminary reports of 2 recent phase II studies with trastuzumab and gemcitabine.
Haddad R; Posner MR
Clin Adv Hematol Oncol; 2003 Apr; 1(4):226-8. PubMed ID: 16224411
[TBL] [Abstract][Full Text] [Related]
34. Systemic therapy in the management of metastatic or advanced salivary gland cancers.
Lagha A; Chraiet N; Ayadi M; Krimi S; Allani B; Rifi H; Raies H; Mezlini A
Oral Oncol; 2012 Oct; 48(10):948-957. PubMed ID: 22698431
[TBL] [Abstract][Full Text] [Related]
35. Clinical trials in a molecular world.
Schellingerhout D; Gelovani J
Neuroimaging Clin N Am; 2006 Nov; 16(4):681-94, ix. PubMed ID: 17148026
[TBL] [Abstract][Full Text] [Related]
36. What is new in the management of salivary gland cancers?
Adelstein DJ; Rodriguez CP
Curr Opin Oncol; 2011 May; 23(3):249-53. PubMed ID: 21330920
[TBL] [Abstract][Full Text] [Related]
37. Strategies for optimizing combinations of molecularly targeted anticancer agents.
Dancey JE; Chen HX
Nat Rev Drug Discov; 2006 Aug; 5(8):649-59. PubMed ID: 16883303
[TBL] [Abstract][Full Text] [Related]
38. New agents in the treatment for malignancies of the salivary and thyroid glands.
Mehra R; Cohen RB
Hematol Oncol Clin North Am; 2008 Dec; 22(6):1279-95, xi. PubMed ID: 19010274
[TBL] [Abstract][Full Text] [Related]
39. Chemotherapy and Targeted Therapy.
Sen M; Prestwich R
Adv Otorhinolaryngol; 2016; 78():148-56. PubMed ID: 27093440
[TBL] [Abstract][Full Text] [Related]
40. Systemic therapy for recurrent or metastatic salivary gland malignancies.
Chintakuntlawar AV; Okuno SH; Price KA
Cancers Head Neck; 2016; 1():11. PubMed ID: 31093341
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
